A Nuevolution BET-BD1 selective inhibitor shows potential anticancer effect with immunotherapy in a mouse model of colorectal cancer
Stockholm, 21 February 2019. Nuevolution AB (publ) (NUE.ST) today announced first animal preclinical data suggesting a potential positive synergistic anticancer effect of combining Nuevolution’s BET-BD1 compound, NUE20798, with an antibody immunotherapy. Nuevolution has developed potent and selective compounds, with a benign safety profile targeting the first bromodomain of the BET family of proteins. Previous data from the program have identified specific genes responsible for human fibrosis to be potently suppressed by our BET-BD1 inhibitors thereby supporting a potential use for such